We have previously shown that FGF1 expression modifies chemosensitivity to cisplatin and carboplatin in multiple ovarian cancer cell lines [4], consistent with data from Ryner et al. [5], describing increased expression of FGF pathway genes in the reactive stroma in chemoresistant ovarian cancer patients. This evidence concerns the gene FGF1 and ovarian carcinoma.